Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 16
- Registration Number
- NCT03661515
- Locations
- 🇪🇸
Hospital San Pedro de Alcántara,, Cáceres, Spain
🇪🇸Hospital la Fe, Valencia, Spain
🇪🇸Hospital Germans Tries i Pujol, Badalona, Badalona, Spain
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
- Conditions
- Acute Myeloid LeukemiaBlasts 10 Percent or More of Bone Marrow Nucleated CellsMyeloproliferative NeoplasmBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHigh Risk Myelodysplastic SyndromeMyeloid SarcomaPhiladelphia Chromosome Positive
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03589729
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
- Conditions
- LeukemiaAdult Lymphoblastic LymphomaAdult Acute Lymphoblastic LeukemiaLeukemia, LymphoblasticLeukemia, T CellLymphoblastic LymphomaLeukemia, AcuteLymphoblastic Leukemia
- Interventions
- Drug: 6-mercaptopurine.Procedure: Bone marrow aspirationProcedure: Intrathecal injectionRadiation: Radiation therapyGenetic: NGSProcedure: allogeneic hematopoietic stem cell transplantationDiagnostic Test: Flow-MRDDiagnostic Test: FISHDiagnostic Test: Flow immunophenotypingDiagnostic Test: KaryotypingDiagnostic Test: PET-CT scan
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT03564704
- Locations
- 🇨🇳
Department of Hematology, Nanfang Hospital, Guangzhou, Guangdong, China
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
- Conditions
- Leukemia, AcuteLeukemia, T CellLeukemia, Lymphoblastic
- Interventions
- Procedure: Bone marrow aspirationProcedure: Intrathecal injectionRadiation: Radiation therapyGenetic: NGSProcedure: allogeneic hematopoietic stem cell transplantationDiagnostic Test: Flow-MRDDiagnostic Test: FISHDiagnostic Test: Flow immunophenotypingDiagnostic Test: Karyotyping
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 70
- Registration Number
- NCT03553238
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Epacadostat, Idarubicin and Cytarabine (EIC) in AML
- Conditions
- AML
- Interventions
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Registration Number
- NCT03444649
- Locations
- 🇨🇭
Departement of Medical Oncology, University Hospital Berne, Berne, Switzerland
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)
- Conditions
- Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: Second phase of inductionDrug: Standard induction therapyDrug: Standard consolidation therapy
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2020-02-05
- Target Recruit Count
- 4000
- Registration Number
- NCT03390387
- Locations
- 🇷🇺
Morozov Children's Municipal Clinical Hospital, Moscow, Russian Federation
🇦🇲prof. R.O.Eolyan Hematology Center, Ereván, Armenia
🇷🇺Transbaikal Regional Oncology Dispensary, Chita, Russian Federation
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia With Myelodysplasia-Related ChangesTherapy-Related Acute Myeloid Leukemia
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 53
- Registration Number
- NCT03330821
- Locations
- 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 322
- Registration Number
- NCT03250338
- Locations
- 🇺🇸
Kansas University, Kansas City, Kansas, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇨🇦University of Alberta, Edmonton, Alberta, Canada
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia
- Interventions
- Other: Laboratory Biomarker AnalysisDrug: Liposome-encapsulated Daunorubicin-CytarabineOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 75
- Registration Number
- NCT03226418
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Recurrent Acute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT03214562
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.